ML-SYS / 2026.07NON-CLINICAL RESEARCH MATERIALSORIGIN DECLARED BY LOT

← Compound index

RM-CVS / Coagulation and vascular signalling

Eptifibatide

Also known as: Integrilin · COR Therapeutics 4

Approved comparator exists

Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.

What this is

Eptifibatide is a synthetic cyclic heptapeptide that blocks platelet glycoprotein IIb/IIIa. The record is anchored to the exact active molecule and labeled intravenous presentations.

Evidence position

Regulated finished products and human clinical evidence support Grade A for the named drug presentations.

What the record does not establish

The label does not authenticate a separately sourced peptide, demonstrate lot purity, or support a different route or formulation.

Sources

  • 01
    Eptifibatide compound recordPubChem
    Shows
    Registry identity, structure, formula and synonyms for eptifibatide
    Does not show
    A registry record does not establish finished-product status or lot quality
  • 02
    Eptifibatide injection prescribing informationDailyMed / U.S. National Library of Medicine
    Shows
    U.S. labeling for defined intravenous eptifibatide strengths and presentations
    Does not show
    Does not qualify a different concentration, container, route or source

External database index

LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE

Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.

PUBMED / FOUND RECORDS

  1. Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke.The New England journal of medicine / 2024 Sep 5PMID 39231343 / DOI 10.1056/NEJMoa2314779
  2. Eptifibatide. / 2006PMID 31260228
  3. Eptifibatide. / 2026 JanPMID 31082110
  4. Delayed-onset eptifibatide-induced thrombocytopenia.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists / 2024 Feb 8PMID 37884759 / DOI 10.1093/ajhp/zxad271
  5. Thrombolysis Alone vs With Argatroban or Eptifibatide: A Prespecified Subgroup Analysis of the MOST Trial.Neurology / 2025 Nov 11PMID 41071964 / DOI 10.1212/WNL.0000000000214228

CLINICALTRIALS.GOV / FOUND RECORDS

  1. Co-administration of Iloprost and Eptifibatide in Septic Shock PatientsCOMPLETED / PHASE2 / Sisse R. Ostrowski, MD PhD DMScNCT02204852 / DIRECT intervention MATCH: Eptifibatide
  2. Study of Otamixaban Versus Unfractionated Heparin (UFH) and Eptifibatide in Non-ST Elevation Acute Coronary SyndromeCOMPLETED / PHASE2 / SanofiNCT00317395 / DIRECT intervention MATCH: Eptifibatide
  3. Multi-arm Optimization of Stroke ThrombolysisCOMPLETED / PHASE3 / Washington University School of MedicineNCT03735979 / DIRECT intervention MATCH: Eptifibatide
  4. EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED)COMPLETED / PHASE3 / Organon and CoNCT00089895 / DIRECT intervention MATCH: Eptifibatide
  5. Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke (CLEAR Stroke) TrialCOMPLETED / PHASE1, PHASE2 / University of CincinnatiNCT00250991 / DIRECT title MATCH: Eptifibatide

Related compounds

RM-CVS

Bivalirudin

Read entry →
RM-CVS

Angiotensin II

Read entry →
RM-CVS

Icatibant

Read entry →